Table 1.

Baseline patient characteristics and drug doses by treatment allocation

CharacteristicPlaceboCholecalciferol
Age (yr)67 (54, 72)60 (53, 71)
Male sex4353
Time on dialysis (mo) 42 (18, 89)38 (25, 66)
Body mass index (kg/m2)a31.3±9.526.6±6.4
Individuals with a previous fracture128
Individuals falling within the previous month15
Caucasoid (%)36.750.0
Diabetesb1815
Cardiovascular diseaseb1917
Peripheral vascular diseaseb1010
Cerebrovascular diseaseb63
Current or ex-smoker1513
Never smoked1517
Calcitriol (µg/d)0.11 (0, 0.25)0.11 (0, 0.25)
Calcium carbonate (g/d) 4.6 (2.2, 9.6)5.2 (1.1, 9)
Sevelamer (g/d) 0 (0, 3)0 (0, 4.2)
Darbepoetin alfa (µg/wk) 40 (15, 85)40 (20, 80)
  • n=30 for each group. Data are given as median (interquartile range), number, or mean ± SD, unless otherwise specified.

  • a P=0.03.

  • b Present or suspected.